Florentine E F Timmer, Bart Geboers, Alette H Ruarus, Laurien G P H Vroomen, Evelien A C Schouten, Susan van der Lei, Danielle J W Vos, Madelon Dijkstra, Hannah H Schulz, Joyce Bakker, Bente A T van den Bemd, Petrousjka M van den Tol, Robbert S Puijk, Birgit I Lissenberg-Witte, Tanja D de Gruijl, Jan J J de Vries, Frank J Lagerwaard, Hester J Scheffer, Anna M E Bruynzeel, Martijn R Meijerink
BACKGROUND: Pancreatic ductal adenocarcinoma is an aggressive disease with a dismal prognosis. Stage III locally advanced pancreatic cancer is considered unresectable and current palliative chemotherapy regimens only modestly improve survival. Guidelines suggest chemoradiation or stereotactic ablative body radiotherapy (SABR) could be beneficial in certain circumstances. Other local treatments such as irreversible electroporation could enhance patient outcomes by extending survival while preserving quality of life...
March 18, 2024: Lancet. Gastroenterology & Hepatology